Episode 38. GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan Blood Cancer Talks

In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota. 
Here are the key trials we discussed:
1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation.
 
https://pubmed.ncbi.nlm.nih.gov/30824040/
 
2. BMT CTN 1703 study: Post-Transplantation Cyclophosphamide-Based GVHD prophylaxis 
 
https://pubmed.ncbi.nlm.nih.gov/37342922/
 
3. Patient-Reported Outcomes of BMT CTN 1703
 
https://ash.confex.com/ash/2023/webprogram/Paper187859.html
 
4. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
 
https://pubmed.ncbi.nlm.nih.gov/37311510/
 
5. BMT CTN 1301 trial: Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
 
https://pubmed.ncbi.nlm.nih.gov/34855460/
 
6. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD (ABA2)
 
https://pubmed.ncbi.nlm.nih.gov/33449816/
 
7. Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus
 
https://ash.confex.com/ash/2023/webprogram/Paper181292.html